Beyond Medical Secures $5M in Private Placement to Fuel Growth and Innovation

Beyond Medical Technologies Inc. (CSE: DOCT) (Frankfurt: 7FM3) has announced the closing of the first tranche of its non-brokered private placement, raising $1,322,500 by issuing 10,580,000 units at a price of $0.125 per unit. Each unit consists of one common share and one share purchase warrant, exercisable at $0.20 per warrant share until February 5, 2023. The company plans to close the final tranche of the non-brokered placement in the coming weeks, aiming to raise a total of $5 million.

The funds raised from the private placement will support Beyond Medical's strategic goals, particularly in the development of its Organivore and Pharmavore waste digesters and medical-grade facemasks. The company's proprietary technology aims to address the growing problem of waste management, particularly in the healthcare industry, by providing efficient and cost-effective solutions. By investing in these technologies, Beyond Medical is positioning itself to capture a significant market share in the waste management sector, which is expected to grow due to increasing waste generation and stricter environmental regulations.

In addition to its waste management solutions, Beyond Medical's subsidiary, Micron Technologies, is manufacturing medical-grade facemasks that comply with ASTM F2100 Standards. The private placement funds will support the expansion of this production line, enabling Beyond Medical to meet the growing demand for high-quality, certified facemasks. This investment aligns with the company's goal of becoming a leading provider of medical-grade personal protective equipment (PPE).

The successful completion of the private placement is expected to have a positive impact on Beyond Medical's financial stability and growth trajectory. The influx of cash will provide the company with additional capital to support its ongoing operations and expansion plans, enhancing its liquidity and financial flexibility. This, in turn, will allow Beyond Medical to better manage its cash flow and respond to market opportunities or challenges that may arise.

The appointment of Michael Kelly to the board of directors in February 2021 has also influenced the company's strategic direction and risk management. Kelly's background in law enforcement and entrepreneurship brings valuable skills in leadership, risk assessment, and problem-solving to the company. His experience in the Canadian Armed Forces and the Royal Canadian Mounted Police (RCMP) has equipped him with valuable skills in navigating complex regulatory landscapes and assessing and mitigating risks. This, combined with his entrepreneurial spirit and strategic approach, can help Beyond Medical explore new markets, develop strategic partnerships, and make data-driven decisions to drive growth and success.

In conclusion, Beyond Medical's private placement funding supports the company's strategic goals by enabling the development and commercialization of its waste digesters, the expansion of its medical-grade facemask production, and providing the company with the financial flexibility to pursue growth opportunities and maintain its competitive position in the market. The appointment of Michael Kelly to the board of directors brings valuable experience in law enforcement and entrepreneurship, which can help the company navigate the complex biopharma and biotech industries, comply with regulations, and drive growth through informed decision-making and strategic partnerships.